Mayne Pharma Group Announces Generic NuvaRing Accepted for Filing by FDA

Mayne Pharma Group Limited (ASX: MYX) announced its Abbreviated New Drug Application (ANDA) for generic NuvaRing® has been accepted for filing by the US Food and Drug Administration (FDA). NuvaRing is an intra vaginal hormonal contraceptive delivery device combining etonogestrel … Continue reading Mayne Pharma Group Announces Generic NuvaRing Accepted for Filing by FDA

AusCann Group Holdings Signs HoA with Leading Wholesale Distributor in Australia

AusCann Group Holdings Ltd (ASX:AC8) announced that it has entered into a Heads of Agreement (HoA) with ASX listed Australian Pharmaceutical Industries Limited (ASX:API) to form a wholesale agreement for the distribution of AusCann’s cannabinoid medicines throughout Australia. The collaboration … Continue reading AusCann Group Holdings Signs HoA with Leading Wholesale Distributor in Australia

Noxopharm Announces NYX-104 Delivers Key Proof-of-Concept in Stroke Animal Model

Noxopharm and its US subsidiary, Nyrada Inc, are pleased to announce jointly that the experimental drug, NYX-104, has cleared a critical step in its development as a neuroprotective drug. Data released today at the 12th Cerebral Vascular Biology International Conference … Continue reading Noxopharm Announces NYX-104 Delivers Key Proof-of-Concept in Stroke Animal Model

Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial

Factor Therapeutics Limited (ASX: FTT), an Australian biomedical company developing therapeutics for advanced wound care, announced passing 50% recruitment in the VF00102 clinical trial. Twice as many patients were enrolled in November than in the previous month, bringing the total … Continue reading Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial